Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Core Viewpoint - Psyence Biomedical Ltd. has entered into a Put Option Agreement with PsyLabs, positioning the company for significant future equity participation in a leading manufacturer of pharmaceutical-grade psychedelics, ensuring a reliable supply as commercialization progresses [1][3]. Group 1: Put Option Agreement Details - The Put Option Agreement allows PsyLabs to require Psyence BioMed to make further equity investments through a share-for-share exchange at fair market value, forming part of a broader strategic relationship [2][4]. - This agreement provides Psyence BioMed with a structured opportunity to acquire a significant equity stake in PsyLabs while securing a reliable supply of pharmaceutical-grade psychedelics for future clinical programs [3][4]. Group 2: Strategic and Commercial Benefits - The agreement enhances Psyence BioMed's clinical development pathway by mitigating supply-chain and regulatory risks, allowing the company to maintain financial flexibility without significant upfront capital deployment [4][5]. - PsyLabs is recognized as one of the most advanced manufacturers of pharmaceutical-grade psychedelic compounds, with expertise in scalable, GMP-compliant production [3][6]. Group 3: Company Background - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies to address unmet mental health needs, being the first of its kind listed on Nasdaq [8]. - PsyLabs is federally licensed to cultivate and export various psychedelic compounds, including psilocybin and ibogaine, to legal medical and research markets, with successful exports to multiple countries [6][7].